111![June 23, 2008 Submit an sNDA for the immunosuppressant Prograf® for Ulcerative Colitis in Japan Japan, June 23, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) to June 23, 2008 Submit an sNDA for the immunosuppressant Prograf® for Ulcerative Colitis in Japan Japan, June 23, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) to](https://www.pdfsearch.io/img/0eda6358ab36792b25993f33a3d33bb2.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2008-09-17 23:51:41
|
---|
112![September 19, 2007 Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation Japan, September 19, [removed]Astellas Pharma Inc. (headquarters: Tokyo, presiden September 19, 2007 Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation Japan, September 19, [removed]Astellas Pharma Inc. (headquarters: Tokyo, presiden](https://www.pdfsearch.io/img/119b33b6da525884b460e479f6daa87f.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2008-09-18 20:50:47
|
---|
113![Brigham and Woman’s Hospital/ Harvard Medical School Boston, USA Department of Translational Medicine (Director: Thomas P. Stossel, MD) and Brigham and Woman’s Hospital/ Harvard Medical School Boston, USA Department of Translational Medicine (Director: Thomas P. Stossel, MD) and](https://www.pdfsearch.io/img/e52ee524ac2a5cf1ad1b97faacdd9633.jpg) | Add to Reading ListSource URL: www.marshallplan.atLanguage: English - Date: 2014-09-30 20:59:05
|
---|
114![Torisel® (temsirolimus) for Kidney Cancer Indication: Torisel is a medication used to treat advanced kidney cancer in adults Dosage: 25 mg Route of administration: Intravenous infusion Schedule: Once a week What is the Torisel® (temsirolimus) for Kidney Cancer Indication: Torisel is a medication used to treat advanced kidney cancer in adults Dosage: 25 mg Route of administration: Intravenous infusion Schedule: Once a week What is the](https://www.pdfsearch.io/img/c008cba12b3a6f7d173c5c18d2e05955.jpg) | Add to Reading ListSource URL: dev66.geckodesigns.comLanguage: English - Date: 2014-10-30 16:14:47
|
---|
115![November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I](https://www.pdfsearch.io/img/ab55005be543bb799573b92121112954.jpg) | Add to Reading ListSource URL: files.shareholder.comLanguage: English |
---|
116![Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance and Dru Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance and Dru](https://www.pdfsearch.io/img/bf4b5b75cbe99e27c618569ed15b62f0.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
117![NIH Public Access Author Manuscript J Natl Cancer Inst. Author manuscript; available in PMC 2009 July 1. NIH-PA Author Manuscript NIH Public Access Author Manuscript J Natl Cancer Inst. Author manuscript; available in PMC 2009 July 1. NIH-PA Author Manuscript](https://www.pdfsearch.io/img/fb790d9cba55e264686fe48c660fbf2c.jpg) | Add to Reading ListSource URL: www.bhdsyndrome.orgLanguage: English - Date: 2011-03-17 20:08:21
|
---|
118![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELIDEL® safely and effectively. See full prescribing information for ELIDEL®. ELIDEL® (pimecrolimus) Cream, 1% fo HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELIDEL® safely and effectively. See full prescribing information for ELIDEL®. ELIDEL® (pimecrolimus) Cream, 1% fo](https://www.pdfsearch.io/img/c155df4245e3ef96e6303609b3f42dac.jpg) | Add to Reading ListSource URL: elidel-us.comLanguage: English - Date: 2014-06-19 10:56:32
|
---|
119![Microsoft Word - Tacrolimus NDA Acceptance Release FINAL.docx Microsoft Word - Tacrolimus NDA Acceptance Release FINAL.docx](https://www.pdfsearch.io/img/d8d07fca205546e4ba49f2d9bcee3067.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2012-12-04 18:27:38
|
---|
120![Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator](https://www.pdfsearch.io/img/cf9a5468f336f16b1fe69cc32fe2cbfd.jpg) | Add to Reading ListSource URL: www.cprit.state.tx.usLanguage: English - Date: 2014-11-20 01:49:18
|
---|